Golden State Equity Partners’s Clearside Biomedical CLSD Stock Holding History

Golden State Equity Partners’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-227	Closed	-$4.32K	–	527
2024 Q3	$4.32K	Buy	+227	New	+$3.88K	﹤0.01%	660
2023 Q3	–	Sell	-1,319	Closed	-$22.2K	–	339
2023 Q2	$22.2K	Hold	1,319	–	–	0.01%	368
2023 Q1	$20.6K	Buy	+1,319	New	+$25.6K	0.01%	213
2022 Q1	$72K	Buy	2,088 +53	+3%	+$1.59K	0.04%	187
2021 Q4	$84K	Buy	+2,035	New	+$132K	0.04%	168

Other funds holding CLSD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Golden State Equity Partners's CLSD Position: Q4 2024 in Review

Golden State Equity Partners sold out of Clearside Biomedical (CLSD) in Q4 2024, closing a stake of 227 shares — an estimated $4.32K sold.

Golden State Equity Partners first reported a position in CLSD in Q4 2021 and held it in 5 quarters. The position peaked at $84K in Q4 2021. 43 funds tracked by Wall St. Rank hold CLSD as of Q4 2024.

Golden State Equity Partners reported no remaining Clearside Biomedical position as of Q4 2024 after selling out during the quarter.
Golden State Equity Partners sold 227 Clearside Biomedical shares in Q4 2024, an estimated $4.32K.
Golden State Equity Partners first reported a position in Clearside Biomedical in Q4 2021 and held it in 5 quarters.
Golden State Equity Partners's Clearside Biomedical position peaked at $84K in Q4 2021.
43 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2024.

Based on Golden State Equity Partners's 13F filing for Q4 2024, filed 24 Jan 2025.